The Cooper Companies, IncNasdaq: COO
Health Care · Health Care Supplies
$67.40
-0.53%
Vol: 1.8M
Research Digest
Tuesday, June 16, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Cooper Companies appointed Paul Keel to its Board of Directors as shares trade near $60, down 25.6% year-to-date ahead of the May 28 earnings release.Neutral▶
Cooper Companies appointed Paul Keel to its Board of Directors and the Audit Committee, bringing senior executive experience from major medical technology and industrial firms. The governance move comes amid weak stock performance, with shares trading around $60, down 15.7% over the past 30 days and 25.6% year-to-date. The company will release its Q2 2026 earnings on May 28, 2026. Analyst consensus remains Buy with an average 12-month price target of $91.07 from 12 analysts. The company operates two business units: CooperVision (contact lenses) and CooperSurgical (fertility and women's healthcare).
May 20Cooper Companies adds Paul Keel to board as shares trade near 26% YTD decline ahead of May 28 earningsMixed▶
Cooper Companies appointed Paul Keel to its Board of Directors on May 4, 2026, with service on the Audit Committee, bringing senior medical technology and industrial executive experience. The stock has been weak, trading around $59-$61 in mid-May, down roughly 16% over the past 30 days and 26% YTD. Cooper's next earnings report is scheduled for May 28, 2026. The company recently reported Q1 2026 revenue of $1.02B and net income of $130.8M, with solid growth in CooperVision (MyDay/MiSight premium lenses) and CooperSurgical, plus $92.5M of share repurchases. Margin expansion benefited from recent reorganizations.
May 19CooperCompanies appoints Paul Keel as independent director effective July 1, 2026 as stock trades near $59-$61 ahead of May 28 earnings reportMixed▶
CooperCompanies appointed Paul Keel as an independent director effective July 1, 2026, who will also serve on the board's Audit Committee. Keel brings senior executive experience from major medical technology and industrial companies, adding governance and financial oversight to the board. The appointment comes as COO shares trade between $59.57 and $61.01, with the stock down 15.7% over the past 30 days, 25.6% YTD, and 25.9% over the past year. The Q2 earnings release is scheduled for May 28, 2026, a key catalyst. Q1 2026 results had shown revenue of $1.02B and net income of $130.8M with global rollout of premium MyDay and MiSight contact lenses, margin expansion, and $92.5M of share repurchases. Average 12-month analyst price target is $91.07 (high $103, low $69).
May 18Cooper Companies trades near $59.61 (May 17), down ~10% MoM and 25.6% YTD, with Q2 2026 earnings due May 28; appointed Paul Keel to its Board on May 4.Negative▶
Cooper Companies stock continues under pressure, trading near $59.61 on May 17, down ~8.4% on the week, ~10% on the month, and 25.6% YTD. The company appointed Paul Keel to its Board of Directors on May 4, 2026, with Keel also joining the Audit Committee. Keel brings experience from senior executive roles at major medical technology and industrial companies. Cooper next earnings report is scheduled for May 28, 2026. Earlier in 2026, the company posted Q1 revenue of $1.02B and net income of $130.8M, with growth in both CooperVision (premium MyDay and MiSight contact lenses) and CooperSurgical segments, along with $92.5M in share repurchases. Analyst sentiment is mixed.
May 15Cooper Companies appoints Envista CEO Paul Keel to board on May 4 as shares remain down 26.1% YoY amid mixed analyst valuation views.Mixed▶
Cooper Companies named Envista CEO Paul Keel to its board of directors on May 4, 2026. The company reported Q1 2026 EPS of $1.10, beating estimates of $1.03 by 6.80%. Next earnings are expected on June 4, 2026 with EPS estimate of $1.10. Shares are down 26.1% over the past year, with analysts mixed on its valuation, highlighting both growth potential and competitive risks. The company is focusing on sustainability through its new MADE BETTER Promise initiative covering CooperVision and CooperSurgical units. Pressure from a struggling vision care market and competitive risks remain key concerns going into the next print.
May 14Cooper Companies hits 52-week low as strategic review continues despite Q1 FY2026 beatMixed▶
Cooper Companies stock recently hit a 52-week low of $61.76 despite reporting strong Q1 FY2026 results on March 5 with revenue of $1.02B (up 6% YoY) and adjusted EPS of $0.18 (up 20% YoY). The company is in the midst of a formal strategic review aimed at identifying opportunities to enhance long-term shareholder value, with fiscal 2026 guidance calling for 4.5–5.5% organic growth and $575–$625M free cash flow. CooperVision continues to benefit from favorable mix shift toward daily disposable and specialty lenses while CooperSurgical delivers stable fertility/surgical growth. The stock decline reflects broader market reactions despite operational strength. Risk centers on whether the strategic review yields actionable outcomes and whether China softness persists.
May 13No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 12No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 11Cooper Companies appointed Envista CEO Paul Keel to its Board of Directors on May 4, 2026.Neutral▶
On May 4, 2026, CooperCompanies announced the appointment of Paul Keel, CEO of Envista, to its Board of Directors. The company's next earnings report is scheduled for May 28, 2026. COO stock recently traded between $60.80-$61.81 on May 8, with shares falling roughly 10% over the past month. Cooper had previously reported strong Q1 results with $1.02B in revenue and raised full-year guidance.
May 8Appoints Envista/Smiths Group/3M veteran Paul Keel to board effective July 1, 2026Neutral▶
Cooper Companies announced May 4 that Paul Keel joins board as independent director effective July 1, 2026, and will serve on Audit Committee. Keel brings extensive medical device and industrial leadership experience including prior CEO roles at Envista Holdings and Smiths Group plus lengthy tenure at 3M. Chair Colleen Jay highlighted his financial expertise strengthening governance. No significant overnight news beyond board appointment. Cooper Companies scheduled to release Q2 FY2026 earnings on May 28, 2026. Stock trades ~$61 on May 8.
May 7Cooper Companies raises FY2026 guidance and appoints Paul Keel to board, announces formal strategic reviewPositive▶
Cooper Companies reported Q1 FY2026 revenue of $1.02 billion, up 6% year-over-year, with adjusted EPS rising 20% to $0.18 driven by margin expansion. Company raised full-year guidance for earnings and free cash flow ($575-625M). The board appointed Paul Keel, CEO of Envista, as independent director effective July 1, 2026. Cooper announced a formal strategic review aimed at identifying value-creation opportunities. Analyst consensus is Buy with $90.18 target representing 40% upside from current levels.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| WSTWEST | $329.11 | -0.70% | +8.3% | 34.5x | 1.18 | $23.3B |
| COOCOOPER | $67.40 | -0.53% | +10.5% | 13.5x | 0.87 | $13.1B |
| ALGNALIGN | $179.56 | +0.73% | +13.1% | 14.5x | 1.67 | $12.9B |
| LLYELI | $1,120.89 | -0.75% | +13.6% | 25.2x | 0.52 | $1.00T |
| JNJJOHNSON | $235.47 | -0.08% | +2.7% | 18.5x | 0.26 | $566.1B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.